DNA vs. WBA

Last updated Jun 3, 2026

DNA (Ginkgo Bioworks Holdings, Inc.) and WBA (Walgreens Boots Alliance, Inc.) are both stocks. Both are in the Healthcare sector — DNA in Biotechnology, WBA in Pharmaceutical Retailers. At a 0.24 correlation, their price movements are largely independent.

Performance

DNA vs. WBA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ginkgo Bioworks Holdings, Inc. (DNA) and Walgreens Boots Alliance, Inc. (WBA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

DNA

• 1D: 2.08%
• 1M: -3.81%
• YTD: 12.27%
• 6M: 8.61%
• 1Y: 30.86%
• 3Y*: -47.59%
• 5Y*: -52.72%
• 10Y*: —

WBA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

DNA vs. WBA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DNA Ginkgo Bioworks Holdings, Inc.	12.27%	-15.38%	-85.47%	0.00%	-79.66%	-17.89%
WBA Walgreens Boots Alliance, Inc.	0.00%	28.40%	-61.34%	-25.09%	-25.06%	-0.28%

Correlation

The correlation between DNA and WBA is 0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.02
Correlation (3Y) Calculated over the trailing 3-year period	0.27
Correlation (5Y) Calculated over the trailing 5-year period	0.24
Correlation (All Time) Calculated using the full available price history since Apr 20, 2021	0.24

Over the past year, the correlation between DNA and WBA has dropped to 0.02 - well below their long-term average of 0.24, suggesting their price drivers have been diverging.

Fundamentals

Total Revenue (TTM) DNA : $121.84M WBA : $154.58B
Gross Profit (TTM) DNA : $99.27M WBA : $26.47B
EBITDA (TTM) DNA : -$218.90M WBA : -$2.92B

Return for Risk

DNA vs. WBA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNA

DNA Risk / Return Rank: 53
DNA Sharpe Ratio Rank: 51
DNA Sortino Ratio Rank: 56
DNA Omega Ratio Rank: 55
DNA Calmar Ratio Rank: 52
DNA Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DNA vs. WBA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Walgreens Boots Alliance, Inc. (WBA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DNA	WBA	Difference
Sharpe ratio Return per unit of total volatility	0.31	—	—
Sortino ratio Return per unit of downside risk	1.14	—	—
Omega ratio Gain probability vs. loss probability	1.14	—	—
Calmar ratio Return relative to maximum drawdown	0.52	—	—
Martin ratio Return relative to average drawdown	0.90	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	DNA	WBA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.31	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.54	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.54	—	—

Drawdowns

Drawdown Indicators

	DNA	WBA	Difference
Max Drawdown Largest peak-to-trough decline	-99.10%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-66.05%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-94.72%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-99.10%	—	—
Current Drawdown Current decline from peak	-98.44%	—	—
Average Drawdown Average peak-to-trough decline	-79.64%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	38.15%	—	—

Volatility

Volatility by Period

	DNA	WBA	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.46%	—	—
Volatility (6M) Calculated over the trailing 6-month period	70.34%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	98.67%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	97.66%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	96.48%	—	—

Dividends

DNA vs. WBA - Dividend Comparison

Neither DNA nor WBA has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
DNA Ginkgo Bioworks Holdings, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
WBA Walgreens Boots Alliance, Inc.	0.00%	0.00%	10.72%	7.35%	5.13%	3.62%	4.64%	3.04%	2.46%	2.13%	1.78%	1.64%

Financials

Frequently Asked Questions

Can I hold both DNA and WBA in my portfolio?

DNA and WBA have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.